Dr. Melanie Rolli is Group CEO of Helsinn Healthcare, a global pharmaceutical company specializing in cancer supportive care and onco-dermatology. She brings over 20 years of international biopharma experience, with a proven track record in product development and global commercialization across pharmaceutical and biotechnology companies.

Before joining Helsinn, Dr. Rolli served as CEO of AELIX Therapeutics and PIQUR Therapeutics, where she led strategic repositioning and successful fundraising initiatives. She previously spent 14 years at Novartis in increasingly senior roles spanning global development, medical affairs, and patient safety.

Dr. Rolli has held both executive and non-executive positions throughout her career, combining operational leadership with board-level strategic oversight in the pharmaceutical and biotech sector.